Find in Library

Low-dose azacitidine, pioglitazone and all-<i>trans</i> retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase

oleh: Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thomas Sudhoff, Jorg Westermann, Marie Luise Hutter-Kronke, Richard F. Schlenk, Daniela Weber, Peter Paschka, Florian Zeman, Hartmut Dohner, Wolfgang Herr, Albrecht Reichle, Simone Thomas